弥漫大B细胞淋巴瘤形态淋巴瘤中MYC重排的高分辨率架构及伙伴基因
对112例弥漫大B细胞淋巴瘤(DLBCL)形态且携带MYC重排的肿瘤进行MYC、BCL2、BCL6及免疫球蛋白(IG)位点靶向测序,在碱基对分辨率刻画MYC重排位置并在88例中鉴定伙伴基因。发现编码区上游及内含子1的「基因簇」重排富集IGH(80%),非基因簇重排多位于MYC基因下游且伙伴多样。两种FISH断裂分离探针在32%病例结果不一致;双打击淋巴瘤中多数MYC重排为非IG伙伴(65%)、断点位于基因簇外(72%)。
要点
- MYC重排断点可分为基因簇(编码区上游及内含子1)与非基因簇,前者80%涉及IGH。
- 非基因簇重排多位于MYC下游,伙伴包括IGL、IGK、BCL6、ZCCHC7及RFTN1。
- 两种FISH断裂分离探针在32%病例结果不一致,包括部分MYC-IGL/IGK重排。
核心结论
- 研究揭示了DLBCL形态淋巴瘤中MYC重排具有临床相关性的架构特征。
- 在DLBCL形态的原发双打击淋巴瘤中,MYC-IG重排较MYC-非IG重排显示至进展时间和总生存更差的趋势。
研究设计与样本
- 对112例DLBCL形态且携带MYC重排的肿瘤进行MYC、BCL2、BCL6及免疫球蛋白(IG)位点靶向测序。
- 在碱基对分辨率刻画MYC重排位置,并在88例中鉴定伙伴基因。
- 比较两种市售FISH断裂分离探针检测MYC位点的结果。
主要发现
- 基因簇重排富集涉及IGH的易位(80%)。
- 非基因簇重排多位于MYC基因下游,伙伴多样,包括IGL、IGK、BCL6、ZCCHC7和RFTN1(RFTN1此前未被描述为MYC伙伴)。
- 两种FISH断裂分离探针在32%受检病例中结果不一致,包括部分MYC-IGL和MYC-IGK重排。
- 在双打击淋巴瘤(HGBL-DH)中,多数MYC重排为非IG伙伴(65%),断点位于基因簇外(72%)。
- 在DLBCL形态的原发HGBL-DH患者中,MYC-IG重排较MYC-非IG重排显示至进展时间和总生存更差的趋势。
关键数值与推荐
- MYC位点基因组重排发生于约12%的DLBCL形态淋巴瘤,并与较差结局相关。
- 基因簇重排中涉及IGH的易位占80%。
- 双打击淋巴瘤中非IG伙伴的MYC重排占65%,基因簇外断点占72%。
- 两种FISH断裂分离探针在32%受检病例中结果不一致。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Genomic rearrangements in the MYC locus occur in ∼12% of lymphomas with diffuse large B-cell lymphoma (DLBCL) morphology and are associated with inferior outcome. Previous studies exploring MYC rearrangements have primarily used fluorescence in situ hybridization (FISH) assays to characterize break-apart status but have rarely examined breakpoint location, and in some cases have not examined partner identity. We performed targeted sequencing of MYC, BCL2, BCL6, and the immunoglobulin (IG) loci in 112 tumors with DLBCL morphology harboring MYC rearrangement. We characterized the location of the MYC rearrangement at base pair resolution and identified the partner in 88 cases. We observed a cluster of breakpoints upstream of the MYC coding region and in intron 1 (the "genic cluster"). Genic cluster rearrangements were enriched for translocations involving IGH (80%), whereas nongenic rearrangements occurred mostly downstream of the MYC gene with a variety of partners, including IGL and IGK Other recurrent partners included BCL6, ZCCHC7, and RFTN1, which has not previously been described as a MYC partner. We compared 2 commercially available FISH break-apart assays for the MYC locus and observed discordant results in 32% of cases examined, including some with MYC-IGL and MYC-IGK rearrangements. In cases of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement (HGBL-DH), so-called "double-hit" lymphomas, the majority of MYC rearrangements had non-IG partners (65%), with breakpoints outside the genic cluster (72%). In patients with de novo HGBL-DH of DLBCL morphology, MYC-IG rearrangements showed a trend toward inferior time to progression and overall survival compared with MYC-non-IG rearrangements. Our data reveal clinically relevant architecture of MYC rearrangements in lymphomas with DLBCL morphology.
引用
- Chong LC, Ben-Neriah S, Slack GW, et al. High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology. Blood Adv. 2018. PMID: 30348671. doi:10.1182/bloodadvances.2018023572
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。